Icatibant Aguettant

Icatibant, the active ingredient in Icatibant Aguettant, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency.

GNH USA supplies Icatibant Aguettant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured product availability across global markets.

Icatibant is used to manage hereditary angioedema, a disorder characterized by bradykinin‑mediated swelling.

- Acute hereditary angioedema (C1‑inhibitor deficiency): provides rapid relief of swelling during an attack. - Hereditary angioedema type I: reduces attack severity and duration. - Hereditary angioedema type II: alleviates symptoms by blocking bradykinin effects.

Icatibant may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headedness. - Fatigue: feeling of tiredness after dosing.

Serious or Rare Side Effects: - Hypersensitivity reactions: rash, urticaria, or anaphylaxis. - Severe injection site necrosis: tissue damage requiring medical attention. - Thrombocytopenia: low platelet count observed in rare cases. - Acute hypertension: sudden rise in blood pressure. - Pulmonary edema: fluid accumulation in lungs, very rare. - Cardiovascular collapse: severe drop in blood pressure and heart function.

Before using Icatibant, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; weigh benefits against possible risks. - Renal impairment: monitor closely as the drug is primarily renally excreted. - Concomitant ACE inhibitors: may increase risk of angioedema; assess necessity. - Hypersensitivity: discontinue immediately if allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect the bradykinin pathway or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin‑mediated angioedema. - Neprilysin inhibitors: increase bradykinin levels, raising risk of swelling.

Moderate Interactions (Monitor Closely): - Estrogen‑containing oral contraceptives: may elevate bradykinin activity. - Other B2 receptor antagonists: additive pharmacodynamic effects. - Drugs affecting renal clearance: may alter icatibant elimination.